About US
Contact us
-
Pfizer close to aquiring Medivation for approximately $14bnDrug giant Pfizer is close to signing a $14bn agreement to acquire biotech firm Medivation. Pfizer has been seeking acqusitions as the sales of its older drugs have slowed down, reported Bloomberg.2016/8/23
-
Deals this week: Omeros Corporation, Cytocentrics, Recro PharmaBio-pharmaceutical companyOmeros Corporationhas announced pricing for a public offering of 3,478,260 shares of its common stock to be $11.5 per share. Omeros is expected to raise gross proceeds of $42016/8/22
-
M&As this week: Mallinckrodt, Scintilla Pharmaceuticals, Lonza GroupMallinckrodt plchas announced plans to acquire Stratatech Corporation, a regenerative medicine company that develops proprietary skin substitute products. The acquisition is expected to strengthen Ma2016/8/22
-
Pfizer's Lyrica success a boon for Northwestern University endowmentPfizer’s Lyrica leads drug sales for the company--but it’s also doing big things for another of the med’s developers. Royalties on the nerve pain and seizure med have powered the endowment at Northwe2016/8/19
-
Merck joins Pfizer, Sanofi in high-stakes hunt for MedivationMerck & Co. wants Medivation, too. Not content to let another Big Pharma snap up the cancer-focused biotech unchallenged, Merck has joined the fight for a prize valued at more than $10 billion. R2016/8/19
-
J&J braces for biosim attack after losing last-ditch Remicade patent fightJohnson & Johnson lost its court battle to shieldRemicade from encroaching biosimilar competition. A U.S. District Judge on Wednesdaystruck down a key patent on the drug, clearing the way for Cell2016/8/18
-
Merck cuts 148 jobs after giving up on ex-blockbuster hopeful ZontivityMerck & Co. ($MRK) has come to the end of the line with Zontivity, a clot-busting med once tagged with $5 billion sales estimates. The drugmaker won't promote the drug anymore in the U.S., and it2016/8/18
-
Vertex trial flop won't hurt chances for $485M revenue boost: AnalystsMonday, Vertex ($VRTX) announced plans to stop a cystic fibrosis trial that was coming up empty. But it wasn’t all bad news for the drugmaker--and analysts even managed to pull out some positives. Ca2016/8/17
-
Orphan drugs used in wider settings come with sizable price hikes, report findsPassed in 1983, the Orphan Drug Act (ODA) has spurred development of hundreds of rare disease drugs that may have not otherwise seen the light of day. But many drugs under the “orphan” umbrella are us2016/8/17
-
On day one of cancer fund overhaul, NICE faces new calls for reformToday is the first day forEngland’s drug cost watchdog to take the reins of the beleaguered Cancer Drugs Fund and the moment it took over, NICEfaced criticism froma top drugmaker over how it intends t2016/8/16